Li Xuan Qin

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Normalization method for transcriptional studies of heterogeneous samples--simultaneous array normalization and identification of equivalent expression
    Li Xuan Qin
    Memorial Sloan Kettering Cancer Center
    Stat Appl Genet Mol Biol 8:Article 10. 2009
  2. pmc Evaluation of methods for oligonucleotide array data via quantitative real-time PCR
    Li Xuan Qin
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    BMC Bioinformatics 7:23. 2006
  3. ncbi request reprint The clustering of regression models method with applications in gene expression data
    Li Xuan Qin
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Biometrics 62:526-33. 2006
  4. pmc Predictors of survival and recurrence in primary leiomyosarcoma
    Rebecca A Gladdy
    Sarcoma Disease Management Team, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 20:1851-7. 2013
  5. pmc Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors
    Jennifer LaFemina
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 20:66-72. 2013
  6. pmc Predicting outcome by growth rate of locally recurrent retroperitoneal liposarcoma: the one centimeter per month rule
    James O Park
    Soft Tissue Sarcoma Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Surg 250:977-82. 2009
  7. doi request reprint Differentially expressed genes in window trials are influenced by the wound-healing process: lessons learned from a pilot study with anastrozole
    Mary Morrogh
    Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Surg Res 176:121-32. 2012
  8. doi request reprint A postoperative nomogram for local recurrence risk in extremity soft tissue sarcomas after limb-sparing surgery without adjuvant radiation
    Oren Cahlon
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 255:343-7. 2012
  9. pmc CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers
    Junwei Chen
    Department of Pathology, Memorial Sloan Kettering Cancer Center, NY, USA
    Genes Chromosomes Cancer 51:186-95. 2012
  10. doi request reprint Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy
    Ryan C Fields
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 18:328-36. 2011

Detail Information

Publications38

  1. pmc Normalization method for transcriptional studies of heterogeneous samples--simultaneous array normalization and identification of equivalent expression
    Li Xuan Qin
    Memorial Sloan Kettering Cancer Center
    Stat Appl Genet Mol Biol 8:Article 10. 2009
    ..Empirical illustration of the proposed method is provided using a liposarcoma study from MSKCC to identify genes differentially expressed between normal fat tissue versus liposarcoma tissue samples...
  2. pmc Evaluation of methods for oligonucleotide array data via quantitative real-time PCR
    Li Xuan Qin
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    BMC Bioinformatics 7:23. 2006
    ..An advantage of our approach over spike-in studies is that methods are validated on a real dataset that was collected to address a scientific question...
  3. ncbi request reprint The clustering of regression models method with applications in gene expression data
    Li Xuan Qin
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Biometrics 62:526-33. 2006
    ..The proposed methodology was applied to two microarray data sets, one from a breast cancer study and the other from a yeast cell cycle study...
  4. pmc Predictors of survival and recurrence in primary leiomyosarcoma
    Rebecca A Gladdy
    Sarcoma Disease Management Team, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 20:1851-7. 2013
    ..Thus, we sought to determine the factors that predict survival and recurrence in patients with primary leiomyosarcoma alone...
  5. pmc Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors
    Jennifer LaFemina
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 20:66-72. 2013
    ..It is controversial whether patients with NF1-associated MPNST have worse outcomes. We investigated the prognostic significance of sporadic, NF1-associated, and RT-induced MPNST...
  6. pmc Predicting outcome by growth rate of locally recurrent retroperitoneal liposarcoma: the one centimeter per month rule
    James O Park
    Soft Tissue Sarcoma Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Surg 250:977-82. 2009
    ..To identify the prognostic variables that predict disease-specific survival and second local recurrence-free survival in patients with recurrent retroperitoneal liposarcoma so as to guide clinical management...
  7. doi request reprint Differentially expressed genes in window trials are influenced by the wound-healing process: lessons learned from a pilot study with anastrozole
    Mary Morrogh
    Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Surg Res 176:121-32. 2012
    ....
  8. doi request reprint A postoperative nomogram for local recurrence risk in extremity soft tissue sarcomas after limb-sparing surgery without adjuvant radiation
    Oren Cahlon
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 255:343-7. 2012
    ..To develop a nomogram based on clinicopathologic factors to quantify the risk of local recurrence (LR) after limb-sparing surgery without adjuvant radiation (RT)...
  9. pmc CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers
    Junwei Chen
    Department of Pathology, Memorial Sloan Kettering Cancer Center, NY, USA
    Genes Chromosomes Cancer 51:186-95. 2012
    ..Our results show that CD133 and CD44 are universally expressed in GIST, and may represent a lineage rather than a cancer stem cell marker...
  10. doi request reprint Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy
    Ryan C Fields
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 18:328-36. 2011
    ..We examine clinicopathologic factors associated with disease-free survival (DFS) in patients with primary and recurrent DFSP and evaluate responses to multimodality therapy...
  11. pmc Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas?
    Rebecca A Gladdy
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 1209, New York, NY 10065, USA
    J Clin Oncol 28:2064-9. 2010
    ..DSS in patients with primary RAS is significantly worse compared with sporadic STS independent of sarcoma histologic type...
  12. pmc Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance
    Grazia Ambrosini
    Laboratory of New Drug Development and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York 10065, USA
    Clin Cancer Res 18:3552-61. 2012
    ....
  13. pmc Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis
    Ryan M Gobble
    Department of Surgery, Sarcoma Disease Management Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Res 71:2697-705. 2011
    ....
  14. ncbi request reprint Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity : a retrospective analysis
    Robert J Canter
    Division of Surgical Oncology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 110:2050-60. 2007
    ..To the authors' knowledge, few studies to date have examined the effect of chemotherapy in patients undergoing pulmonary resection for metastatic STS of the extremity...
  15. pmc Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma
    Mark A Dickson
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 31:2024-8. 2013
    ..In a phase I trial of PD0332991, several patients with WDLS or DDLS experienced prolonged stable disease. We performed an open-label phase II study to determine the safety and efficacy of PD0332991 in patients with advanced WDLS/DDLS...
  16. pmc Gene expression profiles accurately predict outcome following liver resection in patients with metastatic colorectal cancer
    Hiromichi Ito
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America Department of Surgery, Michigan State University, East Lansing, Michigan, United States of America
    PLoS ONE 8:e81680. 2013
    ..The aim of this study was to build a molecular prognostic model based on gene signatures for patients with completely resected hepatic metastases from colorectal cancer (MCRC)...
  17. pmc Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
    Gary K Schwartz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet Oncol 14:371-82. 2013
    ....
  18. pmc Copy number losses define subgroups of dedifferentiated liposarcoma with poor prognosis and genomic instability
    Aimee M Crago
    Sarcoma Disease Management Program, Department of Surgery, Bioinformatics Core, Computational Biology Center, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 18:1334-40. 2012
    ..This study sought to identify copy number alterations (CNA) associated with dedifferentiation of WDLS, with DDLS morphology, and with patient outcomes...
  19. pmc Why do patients with low-grade soft tissue sarcoma die?
    Robert J Canter
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Surg Oncol 15:3550-60. 2008
    ..The patterns of failure and mechanisms of sarcoma-specific death are poorly characterized among the minority of patients with low-grade soft tissue sarcoma (STS) who succumb to disease...
  20. pmc A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients
    Robert J Canter
    Sarcoma Disease Management Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
    Clin Cancer Res 14:8191-7. 2008
    ..To identify prognostic factors related to outcome in 255 patients with synovial sarcoma and to construct a preoperative nomogram to predict the risk of disease-specific death...
  21. doi request reprint Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 53:17-22. 2009
    ..We report a prospective study of secondary leukemia (SL)/myelodysplastic syndrome (MDS) in neuroblastoma (NB) patients treated with > or =5 cycles of dose-intensive chemotherapy...
  22. pmc Phase II study of sorafenib in patients with metastatic or recurrent sarcomas
    Robert G Maki
    Melanoma Sarcoma Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 909, New York, NY 10065, USA
    J Clin Oncol 27:3133-40. 2009
    ..Further evaluation of sorafenib in these and possibly other sarcoma subtypes appears warranted, presumably in combination with cytotoxic or kinase-specific agents...
  23. pmc Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors
    James E Korkola
    Cell Biology Program, Sloan Kettering Institute for Cancer Research, New York, USA
    J Clin Oncol 27:5240-7. 2009
    ..Currently, patients are risk-stratified on the basis of clinical presentation and serum tumor markers. The introduction of molecular markers could improve outcome prediction...
  24. pmc A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers
    Jordan M Winter
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America corrected
    PLoS ONE 7:e40157. 2012
    ..To help researchers sort through the maze of biomarker data, a compendium of ∼2500 published candidate biomarkers in PDA was compiled (PLoS Med, 2009. 6(4) p. e1000046)...
  25. doi request reprint A microRNA survival signature (MiSS) for advanced ovarian cancer
    Karin K Shih
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Gynecol Oncol 121:444-50. 2011
    ..We tested the hypothesis that miRNA expression is associated with overall survival in advanced ovarian cancer...
  26. pmc Improved testing for microsatellite instability in colorectal cancer using a simplified 3-marker assay
    Iyare Esemuede
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 17:3370-8. 2010
    ..However, the optimal assay for MSI status is unknown. We have evaluated a simplified 3-marker assay for MSI and compared it with the 5-marker (NCI) assay to see if technical variations in MSI testing are important...
  27. doi request reprint The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner
    Grazia Ambrosini
    Laboratory of New Drug Development, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Res 68:2312-20. 2008
    ..In conclusion, after DNA damage by Topo I poisons, flavopiridol targets homologous recombination through a p53-dependent down-regulation of Rad51, resulting in enhancement of apoptosis...
  28. doi request reprint Cadherin-catenin complex dissociation in lobular neoplasia of the breast
    Mary Morrogh
    Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 300 E 66th St, New York, NY 10065, USA
    Breast Cancer Res Treat 132:641-52. 2012
    ..Decreasing membranous catenin expression in tandem with increasing levels of TWIST across the spectrum of lobular lesions suggests that CCC dissociation is a progressive process...
  29. doi request reprint Pancreatic cyst fluid protein expression profiling for discriminating between serous cystadenoma and intraductal papillary mucinous neoplasm
    Peter J Allen
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Ann Surg 250:754-60. 2009
    ....
  30. doi request reprint Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 116:3054-60. 2010
    ....
  31. pmc An Empirical Evaluation of Normalization Methods for MicroRNA Arrays in a Liposarcoma Study
    Li Xuan Qin
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
    Cancer Inform 12:83-101. 2013
    ..However, these assumptions are not necessarily appropriate for microRNA expression arrays because they consist of only a few hundred genes and a reasonable fraction of them are anticipated to have disease relevance...
  32. pmc Enteric neural crest differentiation in ganglioneuromas implicates Hedgehog signaling in peripheral neuroblastic tumor pathogenesis
    Timothy R Gershon
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 4:e7491. 2009
    ....
  33. doi request reprint Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies
    Hikmat A Al-Ahmadie
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 32:377-82. 2008
    ..Therefore, similar to the clone M75, NB100-417 can be used as a diagnostic and potentially a prognostic marker in CRCC, with the advantage of its commercial availability...
  34. doi request reprint MDM2 gene amplification is correlated to tumor progression but not to the presence of SNP309 or TP53 mutational status in primary colorectal cancers
    Ann Forslund
    Memorial Sloan Kettering Cancer Center, Department of Surgery, Colorectal Surgery Service, New York, NY 10021, USA
    Mol Cancer Res 6:205-11. 2008
    ..Our results suggest that MDM2 is a promising target for this type of cancer therapy in a substantial subgroup of colorectal cancers...
  35. pmc KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer, New York, New York 10065, USA
    Cancer Res 69:7175-9. 2009
    ..These data provide a basis for the activity of vascular endothelial growth factor receptor-directed therapy in the treatment of primary and radiation-induced AS...
  36. pmc gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity
    Raymond D Meng
    Department of Medicine, Division of Solid Tumor Oncology, Laboratory of New Drug Development, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Res 69:573-82. 2009
    ..Therefore, combining GSIs with chemotherapy may represent a novel approach for treating metastatic colon cancers by mitigating the development of chemoresistance...
  37. pmc Empirical evaluation of data transformations and ranking statistics for microarray analysis
    Li Xuan Qin
    Department of Biostatistics, University of Washington, F 600 Health Sciences Building 1705 NE Pacific Street, Box 357232, Seattle, WA 98195, USA
    Nucleic Acids Res 32:5471-9. 2004
    ..Finally, we find that choice of image analysis software can also substantially influence experimental conclusions...
  38. ncbi request reprint Standardizing global gene expression analysis between laboratories and across platforms
    Theodore Bammler
    Nat Methods 2:351-6. 2005
    ..These findings indicate that microarray results can be comparable across multiple laboratories, especially when a common platform and set of procedures are used...